Eloxx Pharmaceuticals Expected to Post FY2018 Earnings of ($1.41) Per Share (ELOX)
Eloxx Pharmaceuticals (OTCMKTS:ELOX) – Research analysts at Piper Jaffray Companies lowered their FY2018 EPS estimates for shares of Eloxx Pharmaceuticals in a report released on Thursday, November 8th. Piper Jaffray Companies analyst E. Tenthoff now expects that the company will post earnings of ($1.41) per share for the year, down from their prior forecast of ($1.36). Piper Jaffray Companies also issued estimates for Eloxx Pharmaceuticals’ Q4 2018 earnings at ($0.36) EPS, Q2 2019 earnings at ($0.37) EPS, Q4 2019 earnings at ($0.40) EPS and FY2019 earnings at ($1.49) EPS.
Separately, Zacks Investment Research raised shares of Eloxx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $25.25.
Eloxx Pharmaceuticals (OTCMKTS:ELOX) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.03.
A number of institutional investors have recently made changes to their positions in ELOX. Menora Mivtachim Holdings LTD. bought a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at about $29,247,000. BlackRock Inc. bought a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at about $17,914,000. Altshuler Shaham Ltd bought a new stake in Eloxx Pharmaceuticals in the 3rd quarter valued at about $14,349,000. Emerald Mutual Fund Advisers Trust bought a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at about $3,414,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Eloxx Pharmaceuticals in the 2nd quarter valued at about $1,874,000.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.